Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Anti-MOG autoantibodies pathogenicity in children and macaques demyelinating diseases.

Serguera C, Stimmer L, Fovet CM, Horellou P, Contreras V, Tchitchek N, Massonneau J, Leroy C, Perrin A, Flament J, Hantraye P, Demilly J, Marignier R, Chrétien P, Hart B, Boutonnat J, Adam C, Le-Grand R, Deiva K.

J Neuroinflammation. 2019 Nov 30;16(1):244. doi: 10.1186/s12974-019-1637-7.

2.

Biomechanical behaviour of human bile duct wall and impact of cadaveric preservation processes.

Girard E, Chagnon G, Gremen E, Calvez M, Masri C, Boutonnat J, Trilling B, Nottelet B.

J Mech Behav Biomed Mater. 2019 Oct;98:291-300. doi: 10.1016/j.jmbbm.2019.07.001. Epub 2019 Jul 3.

PMID:
31288211
3.

Toxoplasma Hypervirulence in the Rat Model Parallels Human Infection and Is Modulated by the Toxo1 Locus.

Loeuillet C, Mondon A, Kamche S, Curri V, Boutonnat J, Cavaillès P, Cesbron-Delauw MF.

Front Cell Infect Microbiol. 2019 May 1;9:134. doi: 10.3389/fcimb.2019.00134. eCollection 2019.

4.

Mild malformations of cortical development in sleep-related hypermotor epilepsy due to KCNT1 mutations.

Rubboli G, Plazzi G, Picard F, Nobili L, Hirsch E, Chelly J, Prayson RA, Boutonnat J, Bramerio M, Kahane P, Dibbens LM, Gardella E, Baulac S, Møller RS.

Ann Clin Transl Neurol. 2018 Dec 25;6(2):386-391. doi: 10.1002/acn3.708. eCollection 2019 Feb.

5.

A proliferation-inducing ligand-mediated anti-inflammatory response of astrocytes in multiple sclerosis.

Baert L, Benkhoucha M, Popa N, Ahmed MC, Manfroi B, Boutonnat J, Sturm N, Raguenez G, Tessier M, Casez O, Marignier R, Ahmadi M, Broisat A, Ghezzi C, Rivat C, Sonrier C, Hahne M, Baeten D, Vives RR, Lortat-Jacob H, Marche PN, Schneider P, Lassmann HP, Boucraut J, Lalive PH, Huard B.

Ann Neurol. 2019 Mar;85(3):406-420. doi: 10.1002/ana.25415. Epub 2019 Feb 4.

PMID:
30635946
6.

A New Patient-Derived Metastatic Glioblastoma Cell Line: Characterisation and Response to Sodium Selenite Anticancer Agent.

Berthier S, Larrouquère L, Champelovier P, Col E, Lefebvre C, Cottet-Rouselle C, Arnaud J, Garrel C, Laporte F, Boutonnat J, Faure P, Hazane-Puch F.

Cancers (Basel). 2018 Dec 21;11(1). pii: E12. doi: 10.3390/cancers11010012.

7.

Biodistribution and preliminary toxicity studies of nanoparticles made of Biotransesterified β-cyclodextrins and PEGylated phospholipids.

Perret P, Bacot S, Gèze A, Gentil Dit Maurin A, Debiossat M, Soubies A, Blanc-Marquis V, Choisnard L, Boutonnat J, Ghezzi C, Putaux JL, Lancelon-Pin C, Riou LM, Wouessidjewe D.

Mater Sci Eng C Mater Biol Appl. 2018 Apr 1;85:7-17. doi: 10.1016/j.msec.2017.12.017. Epub 2017 Dec 15.

PMID:
29407159
8.

Anticancer properties of sodium selenite in human glioblastoma cell cluster spheroids.

Berthier S, Arnaud J, Champelovier P, Col E, Garrel C, Cottet C, Boutonnat J, Laporte F, Faure P, Hazane-Puch F.

J Trace Elem Med Biol. 2017 Dec;44:161-176. doi: 10.1016/j.jtemb.2017.04.012. Epub 2017 Apr 29.

PMID:
28965572
9.

Surface delivery of tunable doses of BMP-2 from an adaptable polymeric scaffold induces volumetric bone regeneration.

Bouyer M, Guillot R, Lavaud J, Plettinx C, Olivier C, Curry V, Boutonnat J, Coll JL, Peyrin F, Josserand V, Bettega G, Picart C.

Biomaterials. 2016 Oct;104:168-81. doi: 10.1016/j.biomaterials.2016.06.001. Epub 2016 Jun 29.

10.

Guidelines for May-Grünwald-Giemsa staining in haematology and non-gynaecological cytopathology: recommendations of the French Society of Clinical Cytology (SFCC) and of the French Association for Quality Assurance in Anatomic and Cytologic Pathology (AFAQAP).

Piaton E, Fabre M, Goubin-Versini I, Bretz-Grenier MF, Courtade-Saïdi M, Vincent S, Belleannée G, Thivolet F, Boutonnat J, Debaque H, Fleury-Feith J, Vielh P, Egelé C, Bellocq JP, Michiels JF, Cochand-Priollet B.

Cytopathology. 2016 Oct;27(5):359-68. doi: 10.1111/cyt.12323. Epub 2016 May 5.

PMID:
27146425
11.

Guillain-Barré syndrome and cytomegalovirus infection during pregnancy.

Lupo J, Germi R, Jean D, Baccard-Longère M, Casez O, Besson G, Rougé A, Boutonnat J, Schwebel C, Hoffmann P, Morand P.

J Clin Virol. 2016 Jun;79:74-76. doi: 10.1016/j.jcv.2016.04.010. Epub 2016 Apr 14.

PMID:
27105316
12.

[Technical recommendations and best practice guidelines for May-Grünwald-Giemsa staining: literature review and insights from the quality assurance].

Piaton E, Fabre M, Goubin-Versini I, Bretz-Grenier MF, Courtade-Saïdi M, Vincent S, Belleannée G, Thivolet F, Boutonnat J, Debaque H, Fleury-Feith J, Vielh P, Cochand-Priollet B; pour la Société française de cytologie clinique (SFCC), Egelé C, Bellocq JP, Michiels JF; pour l’Association française d’assurance qualité en anatomie et cytologie pathologiques (AFAQAP).

Ann Pathol. 2015 Aug;35(4):294-305. doi: 10.1016/j.annpat.2015.05.019. Epub 2015 Jul 16. French.

PMID:
26188673
13.

Searching for a link between the L-BMAA neurotoxin and amyotrophic lateral sclerosis: a study protocol of the French BMAALS programme.

Delzor A, Couratier P, Boumédiène F, Nicol M, Druet-Cabanac M, Paraf F, Méjean A, Ploux O, Leleu JP, Brient L, Lengronne M, Pichon V, Combès A, El Abdellaoui S, Bonneterre V, Lagrange E, Besson G, Bicout DJ, Boutonnat J, Camu W, Pageot N, Juntas-Morales R, Rigau V, Masseret E, Abadie E, Preux PM, Marin B.

BMJ Open. 2014 Sep 1;4(8):e005528. doi: 10.1136/bmjopen-2014-005528.

14.

Low-flow vascular malformation: contribution of sequential postcontrast MRI acquisitions.

Heck O, Krainik A, Boubagra K, Tahon F, Attye A, Le Bas JF, Boutonnat J, Grand S.

Neurology. 2014 Jul 1;83(1):100-1. doi: 10.1212/WNL.0000000000000544. No abstract available.

PMID:
24982038
15.

Cellular and molecular mechanisms activating the cell death processes by chalcones: Critical structural effects.

Champelovier P, Chauchet X, Hazane-Puch F, Vergnaud S, Garrel C, Laporte F, Boutonnat J, Boumendjel A.

Toxicol In Vitro. 2013 Dec;27(8):2305-15. doi: 10.1016/j.tiv.2013.09.021. Epub 2013 Oct 14.

PMID:
24134853
16.

Anodal iontophoresis of a soluble guanylate cyclase stimulator induces a sustained increase in skin blood flow in rats.

Kotzki S, Roustit M, Arnaud C, Boutonnat J, Blaise S, Godin-Ribuot D, Cracowski JL.

J Pharmacol Exp Ther. 2013 Sep;346(3):424-31. doi: 10.1124/jpet.113.205484. Epub 2013 Jul 9.

PMID:
23838678
17.

[The inter-university learning website: a national university network for online teaching of pathology].

Gauchotte G, Ameisen D, Boutonnat J, Battistella M, Copie C, Garcia S, Rigau V, Galateau-Sallé F, Terris B, Vergier B, Wendum D, Bertheau P; autres universités du réseau; sous l’égide du Collège des pathologistes.

Ann Pathol. 2013 Jun;33(3):162-8. doi: 10.1016/j.annpat.2013.04.004. Epub 2013 May 28. French.

PMID:
23790654
18.

[Specific aspects of immunocytochemistry].

Courtade-Saïdi M, Boutonnat J, Heiny S.

Ann Pathol. 2012 Nov;32(5 Suppl):S92-3. doi: 10.1016/j.annpat.2012.07.024. Epub 2012 Oct 12. French. No abstract available.

PMID:
23127953
19.

Iontophoresis of endothelin receptor antagonists in rats and men.

Roustit M, Blaise S, Arnaud C, Hellmann M, Millet C, Godin-Ribuot D, Dufournet B, Boutonnat J, Ribuot C, Cracowski JL.

PLoS One. 2012;7(7):e40792. doi: 10.1371/journal.pone.0040792. Epub 2012 Jul 13.

20.

Chalcone JAI-51 improves efficacy of synchrotron microbeam radiation therapy of brain tumors.

Bouchet A, Boumendjel A, Khalil E, Serduc R, Bräuer E, Siegbahn EA, Laissue JA, Boutonnat J.

J Synchrotron Radiat. 2012 Jul;19(Pt 4):478-82. doi: 10.1107/S0909049512015105. Epub 2012 May 4.

PMID:
22713877
21.

Cytotoxicity of chalcone derivatives towards glioblastoma.

Champelovier P, Mininno M, Duchamp E, Nicolle E, Curri V, Boumendjel A, Boutonnat J.

Anticancer Res. 2011 Oct;31(10):3213-8. Erratum in: Anticancer Res. 2012 Mar;32(3):1117.

PMID:
21965728
22.

Effects of age, gender and time on receptor expression and anti-Aspergillus functions of human phagocytes.

Aldebert D, Hypolite M, Bal G, Dumestre-Pérard C, Bertini RL, Rolland C, Boutonnat J, Grillot R, Pelloux H, Brion JP.

Cell Immunol. 2011;270(2):230-6. doi: 10.1016/j.cellimm.2011.05.013. Epub 2011 May 27.

PMID:
21703600
23.

Synthesis and biological evaluation of 4-arylcoumarin analogues of combretastatins. Part 2.

Combes S, Barbier P, Douillard S, McLeer-Florin A, Bourgarel-Rey V, Pierson JT, Fedorov AY, Finet JP, Boutonnat J, Peyrot V.

J Med Chem. 2011 May 12;54(9):3153-62. doi: 10.1021/jm901826e. Epub 2011 Apr 13.

PMID:
21488686
24.

Cathodal iontophoresis of treprostinil and iloprost induces a sustained increase in cutaneous flux in rats.

Blaise S, Roustit M, Millet C, Ribuot C, Boutonnat J, Cracowski JL.

Br J Pharmacol. 2011 Feb;162(3):557-65. doi: 10.1111/j.1476-5381.2010.01045.x.

25.

Iodination increases the activity of verapamil derivatives in reversing PGP multidrug resistance.

Barattin R, Gerby B, Bourges K, Hardy G, Olivares J, Boutonnat J, Arnoult C, D'Hardemare AD, Ronot X.

Anticancer Res. 2010 Jul;30(7):2553-9.

PMID:
20682982
26.

Inhibition of c-Jun N-terminal kinase by SP600125: a cDNA microarray analysis.

Champelovier P, El Atifi-Borel M, Issartel JP, Boutonnat J, Berger F, Seigneurin D.

Cancer Genomics Proteomics. 2010 Mar-Apr;7(2):87-92.

PMID:
20335523
27.

[Urinary cytology and polyomavirus infection: a major stake for patients].

Boutonnat J, Pinel N, Janbon B.

Ann Pathol. 2009 Nov;29 Spec No 1:S116-7. doi: 10.1016/j.annpat.2009.07.017. Review. French. No abstract available.

PMID:
19887239
28.

Synchrotron microbeam radiation therapy for rat brain tumor palliation-influence of the microbeam width at constant valley dose.

Serduc R, Bouchet A, Bräuer-Krisch E, Laissue JA, Spiga J, Sarun S, Bravin A, Fonta C, Renaud L, Boutonnat J, Siegbahn EA, Estève F, Le Duc G.

Phys Med Biol. 2009 Nov 7;54(21):6711-24. doi: 10.1088/0031-9155/54/21/017. Epub 2009 Oct 20.

PMID:
19841517
29.

A novel chalcone derivative which acts as a microtubule depolymerising agent and an inhibitor of P-gp and BCRP in in-vitro and in-vivo glioblastoma models.

Boumendjel A, McLeer-Florin A, Champelovier P, Allegro D, Muhammad D, Souard F, Derouazi M, Peyrot V, Toussaint B, Boutonnat J.

BMC Cancer. 2009 Jul 20;9:242. doi: 10.1186/1471-2407-9-242.

30.

Chalcones derivatives acting as cell cycle blockers: potential anti cancer drugs?

Boumendjel A, Ronot X, Boutonnat J.

Curr Drug Targets. 2009 Apr;10(4):363-71. Review.

PMID:
19355861
31.

Autologous platelet concentrates for bone graft enhancement in sinus lift procedure.

Bettega G, Brun JP, Boutonnat J, Cracowski JL, Quesada JL, Hegelhofer H, Drillat P, Richard MJ.

Transfusion. 2009 Apr;49(4):779-85. doi: 10.1111/j.1537-2995.2008.02036.x. Epub 2009 Jan 2.

PMID:
19171004
32.

Significance of low levels of thyroglobulin in fine needle aspirates from cervical lymph nodes of patients with a history of differentiated thyroid cancer.

Borel AL, Boizel R, Faure P, Barbe G, Boutonnat J, Sturm N, Seigneurin D, Bricault I, Caravel JP, Chaffanjon P, Chabre O.

Eur J Endocrinol. 2008 May;158(5):691-8. doi: 10.1530/EJE-07-0749.

PMID:
18426828
33.

Flavonoids as RTK inhibitors and potential anticancer agents.

Teillet F, Boumendjel A, Boutonnat J, Ronot X.

Med Res Rev. 2008 Sep;28(5):715-45. Review.

PMID:
18080331
34.

[Early detection of leptomeningeal metastasis in patients with metastatic breast carcinoma: validation of CA 15-3 measurement in cerebrospinal fluid].

Gauchez AS, Pez E, Boutonnat J, Bourre JC, Pelletier L, Payan R, Mousseau M.

Ann Biol Clin (Paris). 2007 Nov-Dec;65(6):653-8. French.

35.

2-Arylidenedihydroindole-3-ones: design, synthesis, and biological activity on bladder carcinoma cell lines.

Gerby B, Boumendjel A, Blanc M, Bringuier PP, Champelovier P, Fortuné A, Ronot X, Boutonnat J.

Bioorg Med Chem Lett. 2007 Jan 1;17(1):208-13. Epub 2006 Oct 16.

PMID:
17049235
36.

A pilot study in two French medical schools for teaching histology using virtual microscopy.

Boutonnat J, Paulin C, Faure C, Colle PE, Ronot X, Seigneurin D.

Morphologie. 2006 Mar;90(288):21-5.

PMID:
16929817
37.

Intracellular oxidative response of human monocytes and granulocytes to different strains of Aspergillus fumigatus.

Pastor A, Gafa V, Boutonnat J, Grillot R, Ambroise-Thomas P, Aldebert D.

Mycoses. 2006 Mar;49(2):73-9.

PMID:
16466437
38.

Piperazinobenzopyranones and phenalkylaminobenzopyranones: potent inhibitors of breast cancer resistance protein (ABCG2).

Boumendjel A, Nicolle E, Moraux T, Gerby B, Blanc M, Ronot X, Boutonnat J.

J Med Chem. 2005 Nov 17;48(23):7275-81.

PMID:
16279786
39.

Usefulness of PKH fluorescent labelling to study leukemic cell proliferation with various cytostatic drugs or acetyl tetrapeptide--AcSDKP.

Boutonnat J, Faussat AM, Marie JP, Bignon J, Wdzieczak-Bakala J, Barbier M, Thierry J, Ronot X, Colle PE.

BMC Cancer. 2005 Sep 20;5:120.

40.

Optimization of PKH67 labeling conditions for proliferation monitoring in daunorubicin-treated leukemic cells.

Barbier M, Morjani H, Muirhead KA, Ronot X, Boutonnat J.

Oncol Rep. 2005 Aug;14(2):553-9.

PMID:
16012744
41.

Intra-serous haematopoiesis.

Vaunois B, Breyton M, Seigneurin D, Boutonnat J.

In Vivo. 2005 Mar-Apr;19(2):407-15.

42.

Non-toxic and short treatment with gemcitabine inhibits in vitro migration of HT-1080 cells.

Alcouffe C, Boutonnat J, Clément-Lacroix J, Mousseau M, Ronot X.

Anticancer Drugs. 2004 Sep;15(8):803-7.

PMID:
15494643
43.

[Breast carcinoma with predominant neuroendocrine differentiation].

Frachon S, Pasquier D, Treilleux I, Seigneurin D, Ringeisen F, Rosier P, Bolla M, Boutonnat J.

Ann Pathol. 2004 Jun;24(3):278-83. Review. French.

PMID:
15480266
44.

Fluorescence-based assessment of LRP activity: a comparative study.

Durdux M, Grunwald D, Gautier T, Ronot X, Boutonnat J.

Anticancer Res. 2004 Mar-Apr;24(2B):725-32.

45.

A flow cytometric assay for simultaneous assessment of drug efflux, proliferation, and apoptosis.

Barbier M, Gray BD, Muirhead KA, Ronot X, Boutonnat J.

Cytometry B Clin Cytom. 2004 May;59(1):46-53.

46.

Severe clinical forms of cytochrome b-negative chronic granulomatous disease (X91-) in 3 brothers with a point mutation in the promoter region of CYBB.

Stasia MJ, Brion JP, Boutonnat J, Morel F.

J Infect Dis. 2003 Nov 15;188(10):1593-604. Epub 2003 Nov 4.

PMID:
14624387
47.

Modulation of P-glycoprotein-mediated multidrug resistance by flavonoid derivatives and analogues.

Hadjeri M, Barbier M, Ronot X, Mariotte AM, Boumendjel A, Boutonnat J.

J Med Chem. 2003 May 22;46(11):2125-31.

PMID:
12747785
48.

Modelling of cell proliferation: nuclear versus membrane labelling.

Barbier M, Laurier JF, Seigneurin D, Ronot X, Boutonnat J.

C R Biol. 2002 Apr;325(4):393-400.

49.

TIMP-1/MMP-9 imbalance in an EBV-immortalized B lymphocyte cellular model: evidence for TIMP-1 multifunctional properties.

Gaudin P, Trocmé C, Berthier S, Kieffer S, Boutonnat J, Lamy C, Surla A, Garin J, Morel F.

Biochim Biophys Acta. 2000 Dec 11;1499(1-2):19-33.

50.

Nucleus labeling or membrane labeling for studying the proliferation of drug treated cells?

Boutonnat J, Barbier M, Ronot X, Seigneurin D.

Morphologie. 2000 Jun;84(265):11-5.

PMID:
11048293

Supplemental Content

Loading ...
Support Center